How safe is menopause hormone therapy? Risks in context

What changed on the label in 2026

On February 12, 2026, the FDA announced approved labeling changes that removed statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning on six menopausal hormone therapy products, after starting the review in November 2025. The FDA's announcement cited research showing that women who start therapy within 10 years of menopause onset, generally before 60, had lower all-cause mortality and fewer fractures.

This does not mean the risks disappeared. They are still described in the full prescribing information, and the right choice for you still depends on your history, which is why an individual risk discussion remains the core of a hormone therapy visit.

Breast cancer: why the type of hormone matters

The Women's Health Initiative tested two regimens. According to the National Cancer Institute, estrogen plus a synthetic progestin was associated with more breast cancer, and that elevated risk could persist for years after stopping. Estrogen alone, given to women without a uterus, was associated with a lower risk of breast cancer and breast cancer death. Combined therapy also increased breast density, which can make mammograms harder to read.

Whether micronized progesterone carries a different breast risk from synthetic progestins is an active question with some reassuring observational data but no definitive trial. Keep up with routine breast screening while on therapy. A personal history of hormone-sensitive breast cancer generally rules out systemic therapy, and a strong family history or a BRCA mutation calls for a more detailed, often specialist-informed conversation.

Blood clots and stroke

Both estrogen alone and combined therapy were linked to higher rates of stroke and blood clots in the WHI, for as long as therapy continued. Oral estrogen is processed by the liver first, which raises clotting factors; observational studies suggest that estrogen absorbed through the skin has a smaller effect on clot risk. That is one reason clinicians often choose a patch, gel or cream for women with higher weight, migraine or other risk factors.

A previous blood clot, known clotting disorder such as factor V Leiden, prior stroke or heart attack, or uncontrolled high blood pressure changes the decision significantly and may rule out systemic estrogen.

Protecting the uterine lining

Estrogen without a progestogen raises the risk of endometrial cancer in women who still have a uterus, so a progestogen is added. HealifyMD prescribes micronized progesterone for this purpose. Skipping it, or swapping capsules for a cream without your clinician's agreement, is not a safe shortcut; progesterone creams have weaker evidence for protecting the lining. Unexpected or persistent bleeding on therapy should always be reported.

Vaginal estrogen is a different risk category

Low-dose vaginal estrogen treats dryness, painful sex and urinary symptoms with minimal absorption into the bloodstream, so it does not carry the same systemic concerns as pills or patches. It is generally considered reasonable for long-term use. For women with a history of breast cancer, especially those taking aromatase inhibitors, the decision should be made together with the oncology team.

Compounded hormones, pellets and bioidentical claims

Bioidentical means a hormone matches the structure of your own; it is not a safety rating, and many FDA-approved products are already bioidentical. Compounded hormones are not FDA-approved or FDA-reviewed for safety, effectiveness or quality. The Menopause Society recommends FDA-approved hormone therapy over compounded preparations when an approved product meets your needs. Hormone pellets implanted under the skin are not FDA-approved for menopause therapy and can produce unpredictable, sometimes very high, hormone levels.

Putting your own risk in perspective

Averages from large trials are a starting point, not a forecast for you. A healthy 52-year-old with severe night sweats and no clotting or cancer history is in a very different position from a 68-year-old with a prior stroke. Your clinician looks at your age, time since your last period, blood pressure, weight, smoking status, migraine history, personal and family history of breast cancer and clots, and your baseline labs.

From there, the choices that most affect risk are which estrogen route you use, which progestogen protects the uterus, the dose and how often the plan is reviewed. Ask your clinician to explain why they recommend a particular combination for you, and revisit the decision each year as your health and goals change.